Quick Specifications Class: Triple Hormone Receptor Agonist Targets: GLP-1, GIP, and Glucagon (GCG) Format: 10mg Lyophilized Peptide Clinical Status: Phase 3 Research (Estimated 2026 completion) Performance Comparison Retatrutide represents the new ceiling of weight loss potential
Wait at least 30 minutes before eating food, drinking anything other than plain water, or taking any other oral medications
Trial populations and endpoints varied across studies, and individual outcomes differ, whether the semaglutide dispensed is a branded product or a compounded formulation
In March 2025, BioAge Labs raised nearly $200 million in its IPO to support the development of its apelin receptor agonist pipeline targeting obesity and muscle function
Reliable Delivery: Designed to dispense a consistent volume during research procedures
The anticipation is that ongoing research and development in this field will equip biomedical scientists and clinical practitioners with innovative strategies and insights for combating obesity more effectively, marking a significant stride towards a holistic approach to obesity medicine
